Prognostic factors for progression in atypical meningiomaShakir I. Shakir, Marie‐Christine Guiot, Luís Souhami et al.|Journal of neurosurgery|2018Cited by 65
Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institutionM. Azoulay, Bassam Abdulkarim, Kevin Petrecca et al.|Radiation Oncology|2015Cited by 21
A Phase 2 Study of Neo-adjuvant Metformin and Temozolomide followed by Hypofractionated Accelerated RadioTherapy (HART) with Concomitant and Adjuvant Metformin and Temozolomide (TMZ) in Patients with GlioblastomaGeorge Shenouda, Bassam Abdulkarim, Luís Souhami et al.|International Journal of Radiation Oncology*Biology*Physics|2020Cited by 7
Phase II propensity-matched controlled trial evaluating metformin as an adjunct to neo-adjuvant, concomitant, and adjuvant temozolomide and hypofractionated-accelerated radiotherapy (M-HART) in glioblastoma patients (NCT02780024).George Shenouda, Luís Souhami, Roberto J. Diaz et al.|Journal of Clinical Oncology|2025Cited by 3
A Phase 2 Trial of Neoadjuvant Temozolomide (TMZ) Followed By Accelerated Hypofractionated Radiation Therapy (AHRT) and TMZ Followed By Adjuvant TMZ in Patients with Newly Diagnosed Glioblastoma (GBM): Long Term Survival and Toxicity AnalysisGeorge Shenouda, Bassam Abdulkarim, Luís Souhami et al.|International Journal of Radiation Oncology*Biology*Physics|2018Cited by 2